Tempus AI account plan
AI-powered precision medicine platform
At a glance
Tempus AI is a Chicago-based AI diagnostics and healthcare data company with $1,271.8 million FY2025 revenue and more than 3,800 employees.
Tempus AI is a Chicago-based healthcare technology company that runs molecular diagnostic labs (mostly NGS in oncology, plus hereditary testing) and licenses its de-identified multimodal patient database and AI models to pharma and biotech. Its network covers more than 55% of U.S. oncologists and more than 5,000 institution sites, and it works with 19 of the 20 largest public pharmaceutical companies. FY2025 revenue was $1,271.8 million (2024: $693.4 million), with a net loss of $245.0 million and adjusted EBITDA of $(7.4) million. It had more than 3,800 employees at end-2025. Founded by Eric Lefkofsky in 2015, it listed on Nasdaq (TEM) in June 2024; dual-class stock gives the founder, CEO and chairman voting control.
Business units
Diagnostics
about 75% of FY2025 revenue ($955.4 million, computed)Oncology NGS tests (xT, xR, xF liquid biopsy, xM MRD), hereditary tests from Ambry Genetics and pharmacogenomics, sold to physicians, genetic counsellors, academic medical centers and biopharma. Revenue grew 111% in FY2025, helped by Ambry, and Q3 2026 revenue was $303.5 million (+20%). It is led by Tom Schoenherr, CEO of Diagnostics.
Data and applications
about 25% of FY2025 revenue ($316.4 million, computed)Licenses de-identified clinical, molecular and imaging data and models to life sciences customers through Lens (Insights), and runs Trials (TIME), the Next care-gap platform and Algos. Revenue grew 31% in FY2025 and 33% in Q3 2026 to $108.1 million. It is led by Ryan Fukushima, CEO of Data and Apps.
Strategic priorities
- About 25% long-term growth
- Management prefers long-term growth of about 25% a year to a short-term 30% that decelerates; FY2026 revenue guidance is $1.60-$1.605 billion, about 25% growth.
- Higher diagnostics reimbursement
- FDA approval of the tumor-only xT CDx (May 2026) is expected to give about $80 million of uplift in oncology ASP in 2027, and xF is still in FDA review. The goal is to bring reimbursement per assay more in line with FMI and Guardant.
- Multi-year pharma data and model deals
- Pharma customers are moving from episodic deals to multi-year collaborations and Lens subscriptions with rented GPU clusters. Data licensing bookings exceeded $550 million year to date in 2026, including BMS (up to $137.5 million over five years).
- Expansion beyond oncology
- Tempus is extending into neuropsychiatry, cardiology, rare disease and Alzheimer's data; Pathos pays $55 million over five years for an Alzheimer's dataset, and two FDA 510(k) clearances (ECG-PH and ECG-MR) extend its AI cardiology footprint.
- AI throughout diagnostics and Algos
- The company aims to embed generative and agentic AI in every aspect of diagnostics and to sell clinical-grade Algos through its provider network; Algos are attached to more than 40% of orders.
- Profitability and positive free cash flow
- Adjusted EBITDA turned positive at $25.6 million in Q3 2026, with about $65 million expected for FY2026; about two-thirds of incremental gross profit is reinvested, and free cash flow should turn positive around the end of 2026.
Latest results
In Q3 2026 (quarter ended September 30, 2026) revenue was $411.5 million, up 23% from $334.2 million in Q3 2025. Diagnostics grew 20% to $303.5 million on 32% oncology volume growth, while hereditary revenue grew only 3%; Data and applications grew 33% to $108.1 million, with Insights up 29%. Net loss narrowed to $14.9 million from $80.0 million, and adjusted EBITDA reached $25.6 million against $1.5 million. Nine-month revenue was $1,142.1 million (2025: $904.6 million). Tempus raised FY2026 revenue guidance to $1.60-$1.605 billion and kept adjusted EBITDA guidance at about $65 million; cash and marketable securities were $854.4 million.
Investments and deals
- Personalis acquisition (pending)
- Merger agreement announced July 20, 2026 at $16.25 per share, an enterprise value of $1.5 billion, mainly in stock with up to 50% in cash; it has cleared regulatory review and the shareholder vote is planned for November 30, 2026.
- Ambry Genetics
- Closed February 3, 2025 for $375.0 million cash plus 4,843,136 shares, adding hereditary testing that ran about 460,500 tests and added $362.7 million of revenue in 2025.
- Paige, OneOme and Center Health
- Paige (digital pathology AI, $101.5 million fair value, August 2025), OneOme (pharmacogenetics and a Minneapolis lab, November 2025) and Center Health (August 7, 2026, $5.4 million cash plus shares).
- Foundation model and compute
- An oncology foundation model built with AstraZeneca and Pathos runs on about 1,008 H200 GPUs; Pathos pays $200 million of data licence fees over three years.
- Convertible financing
- $750.0 million of 0.75% convertible notes due 2030 (July 2025) and $460.0 million of 0.00% convertible notes due 2032 (May 2026), of which $317.9 million repaid the remaining Ares term loan and revolver.
Challenges and risks
- Payer reimbursement
- Payment has been received on about 55% of clinical oncology NGS tests and 50% of hereditary tests performed in 2023-2024; possible FDA changes on LDTs add regulatory risk.
- Accumulated losses and debt
- The accumulated deficit was $2.5 billion at September 30, 2026, and year-end 2025 indebtedness was $1.3 billion.
- MRD economics and Personalis integration
- Personalis loses money on the MRD tests it runs; per-test gross profit is expected to turn positive around mid-2027, and new risk factors cover integration and key-employee retention.
- Hereditary growth slowdown
- Hereditary revenue grew only 3% in Q3 2026 as the business laps last year's share gains.
- Competition, data access and litigation
- Competitors include Foundation Medicine, Guardant, Natera, Flatiron and IQVIA; continued access to de-identified data, privacy laws and a Guardant patent suit filed in June 2024 are named risks.
What leadership says
“We've always said we're more interested in long-term 25% growth than we are in kind of short-term 30% growth that then decelerates.”
“It's gone from like not sticky to crazy sticky.”
“Our data business is big and growing, and we have almost no competition.”
“Our compute capacity is probably equal to all of pharma combined.”
Where a supplier can help
- Cloud, storage and compute cost control
- Tied to the foundation model investment and data growth: SG&A growth in Q3 2026 included higher cloud storage and software costs, so suppliers of storage optimisation, GPU capacity or FinOps tooling have a clear entry point.
- Revenue cycle and payer collections
- Tied to the reimbursement challenge: with payment received on only about half of clinical tests, billing, denial management and payer contracting support maps directly to a stated risk.
- Integration of acquired labs and teams
- Tied to the Personalis, Ambry, Paige, OneOme and Center Health deals: integration services, lab systems harmonisation and HR or retention tooling support a company absorbing several acquisitions.
- Pharma-facing data platform tooling
- Tied to the priority on multi-year pharma data and model deals: security, privacy compliance and data governance tools help keep de-identified data licensable under HIPAA and GDPR.
- Sales enablement for clinical reps
- Tied to the push for oncology volume and MRD: a field sales force of about 205 clinical reps with a land-and-expand model is a fit for CRM, territory and sales enablement offers.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Tempus AI?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Tempus AI Annual Report on Form 10-K for fiscal year 2025
- Tempus AI is a Chicago-based healthcare technology company that sells "Intelligent Diagnostics": lab tests (mostly NGS in oncology) connected to patients' clinical data, plus licensing of its de-identified multimodal database to pharma and biotech. It reports one operating segment and two product lines: Diagnostics and Data and applications.
- FY2025 revenue was $1,271.8 million, up from $693.4 million in 2024 (83%); Diagnostics $955.4 million (+111%), Data and applications $316.4 million (+31%). Net loss narrowed to $245.0 million (2024: $705.8 million); adjusted EBITDA was $(7.4) million vs $(104.7) million.
- The February 2025 acquisition of Ambry Genetics ($375.0 million cash plus 4,843,136 shares) added hereditary testing: 460,500 hereditary tests in 2025, adding $362.7 million of Diagnostics revenue. Oncology tests rose from about 270,800 to about 340,500, with average reimbursement up from about $1,510 to about $1,600.
- The data business has a Remaining TCV of more than $1.1 billion, Net Revenue Retention of about 126% for 2025, and works with 19 of the 20 largest public pharmaceutical companies. Strategic deals: AstraZeneca/Pathos foundation model ($200 million data licence fees over three years, plus a $35 million fee), AstraZeneca MSA ($220 million minimum), GSK ($180 million minimum), Recursion (up to $160 million).
- The platform has more than 700 data connections across more than 5,000 institution sites and covers more than 55% of U.S. oncologists. The database holds more than 8.6 million de-identified patient records and more than 450 petabytes of data.
- 2025 M&A and financing: Paige (digital pathology AI, $101.5 million fair value), OneOme (pharmacogenetics, November 2025), $750.0 million of 0.75% convertible notes due 2030, and a $500.0 million ATM program ($195.5 million raised in 2025).
- More than 3,800 employees at end-2025, including about 205 clinical sales reps and about 30 Data and applications sales executives. Cash, cash equivalents and restricted cash were $609.5 million against $1.3 billion of indebtedness.
- Key risks: continued losses (accumulated deficit $2.4 billion), payer reimbursement (payment received on about 55% of clinical oncology NGS tests), access to and monetisation of de-identified data, LDT regulation, competition from Foundation Medicine, Guardant, Natera, Flatiron and IQVIA, the Guardant patent suit, and dependence on founder, CEO and chairman Eric Lefkofsky, who controls the vote through dual-class stock.
- Tempus AI Quarterly Report on Form 10-Q for Q3 2026 (quarter ended September 30, 2026)
- Q3 2026 revenue was $411.5 million, up from $334.2 million in Q3 2025. Diagnostics was $303.5 million (+20%) and Data and applications $108.1 million (+33%). Nine-month revenue was $1,142.1 million (2025: $904.6 million).
- Oncology tests rose from about 77,000 to about 101,500 in the quarter, adding $38.1 million of revenue. Hereditary tests rose from about 140,000 to about 143,000, adding $3.7 million.
- Data and applications growth came from Insights (+$19.9 million) and Next (+$6.4 million). Nine-month growth was helped "specifically" by the Pathos foundation model agreement.
- Q3 net loss was $14.9 million (Q3 2025: $80.0 million). Adjusted EBITDA was $25.6 million (Q3 2025: $1.5 million); nine-month adjusted EBITDA was $30.8 million.
- Pending acquisition: Personalis, at $16.25 per share and an enterprise value of $1.5 billion, mainly in stock with up to 50% in cash, expected to close in Q4 2026. Center Health was acquired on August 7, 2026.
- Financing: $460.0 million of 0.00% convertible notes due 2032 (May 2026). These raised $442.0 million net, of which $317.9 million repaid the remaining Ares term loan and revolver. Cash, cash equivalents and restricted cash were $595.2 million at September 30, 2026.
- Contracts: the AstraZeneca MSA term now runs through December 31, 2028. The Recursion agreement was amended in September 2026: $42.0 million remains over three years, up to $118.0 million in total, with no termination for convenience. Pathos paid $17.5 million of fees in its Series D preferred stock.
- Since inception, more than 9,000 physicians have used Tempus offerings. It works with over 250 biotechs and 19 of the 20 largest public pharma companies.
- Tempus Reports Third Quarter 2026 Results (press release, Exhibit 99.1)
- Q3 2026 revenue was $411.5 million (+23%). Diagnostics was $303.5 million (+20%): oncology volume grew 32%, while hereditary revenue grew only 3%. Data & Applications was $108.1 million (+33%), with Insights up 29%.
- Gross profit rose 27% to $266.7 million. Net loss was $(14.9) million (Q3 2025: $(80.0) million), including $50.8 million of stock compensation and payroll taxes and $42.8 million of unrealized gains on securities.
- Adjusted EBITDA was $25.6 million (Q3 2025: $1.5 million). Non-GAAP net income was $13.4 million.
- Guidance raised: FY2026 revenue of $1.60 to $1.605 billion (about 25% growth), and adjusted EBITDA still about $65 million.
- MRD volume was about 12,000 tests (+300%).
- BMS collaboration (October): Tempus licenses oncology data and models to BMS for up to $137.5 million over five years. BMS and Pathos also license Alzheimer's/dementia data for $55 million over five years. Data licensing bookings exceed $550 million year to date.
- Multi-year collaboration with Merck and Moderna to support the potential commercialization of intismeran autogene (an individualized neoantigen therapy).
- The Personalis acquisition has cleared regulatory review; the shareholder vote is planned for November 30, 2026. Two FDA 510(k) clearances were received (ECG-PH and ECG-MR). Cash and marketable securities were $854.4 million.
- Tempus AI Q3 2026 earnings call transcript
- Lefkofsky called Q3 2026 "an incredibly strong quarter": revenue of $411.5 million (+23%), oncology revenue of $172.6 million (+28%) on 32% volume growth, hereditary revenue of $111.3 million, and Data and apps revenue of $108.1 million (+33%).
- Data deals: BMS licenses oncology data and models for up to $137.5 million over five years, and Pathos pays $55 million for an Alzheimer's dataset, $192.5 million of additional revenue over about five years. "If we sign just one of these big collaborations, we would be content. We've signed three this year alone."
- On profitability: "This quarter, we made the turn." Adjusted EBITDA was $25.6 million and cash and marketable securities $854.4 million. FY2026 guidance was raised to $1.60-$1.605 billion, with adjusted EBITDA still about $65 million.
- Growth target: long-term growth of about 25% a year rather than a short-term 30%. "We think we're building a really large business."
- CFO Jim Rogers: xT tumor-only FDA approval gives "about $80 million of uplift in oncology ASP in 2027". xF is still in FDA review. About two-thirds of incremental gross profit is reinvested.
- MRD and Personalis: the big unlock is reaching positive gross profit per test, perhaps mid-2027. "We will be number one or number two in MRD, I think."
- Data stickiness: pharma customers subscribe to Lens and rent GPU clusters (e.g. 32 or 64 GPUs for three years). "It's gone from like not sticky to crazy sticky."
- Data scale: more than 600 PB, about 8,000 connected providers, and about 50 million patients, more than 80% outside oncology. The TIME trial network is now enterprise-focused, and Lefkofsky does not expect it to become "a billion-dollar business."
- Tempus AI Investor Day 2026 transcript
- At Tempus's first Investor Day (May 29, 2026), Lefkofsky said Tempus has both the proprietary data and the distribution network needed to bring AI to medicine. The data covers over 500 PB and over 45 million patients, with over 400,000 rich multimodal records, from more than 5,000 connected institutions.
- FDA approval of xT CDx (tumor-only) the same morning means the FDA-approved portfolio covers 100% of Tempus's DNA testing. Lefkofsky called it about $200 of ASP lift, received at the beginning of 2027. xF is with the FDA.
- Diagnostics (CFO Jim Rogers): Q1 oncology volume grew about 28%. A 25% growth rate over three years would bring Diagnostics to about $1.9 billion. Algos are attached to more than 40% of orders.
- Hereditary (Diagnostics CEO Tom Schoenherr): over 70 million Americans meet NCCN testing criteria, against 1.5-2 million tests a year. The Care platform runs at about 250 sites. About 1,700 genetic counsellors order Tempus tests.
- Data and Apps (CEO Ryan Fukushima): Lens now has AI co-pilots. Customers cite returns of 30x-50x on single projects. The business has signed more than $2 billion of data licensing deals and grew from 35 customers in 2020 to about 240 in 2025. The top-5 share fell from 85% to 59%.
- Rogers: 2026 guidance of $1.59-$1.6 billion revenue and $65 million adjusted EBITDA. Net Revenue Retention was 126% and TCV more than $1.1 billion. Data is expected to grow about 30% in 2026. Two-thirds of incremental gross profit will be reinvested, and free cash flow should turn positive around the end of the year.
- Foundation model with AstraZeneca and Pathos: about 1,008 H200 GPUs. "Our compute capacity is probably equal to all of pharma combined."
- Applications (Next, TIME, cardiology Algos) operate at scale but "just don't generate lots of money" yet. Lefkofsky believes Algos will "eventually be probably the largest of all of our businesses by far."
Questions about Tempus AI
What does Tempus AI do?
Tempus AI runs molecular diagnostic labs, mainly oncology NGS and hereditary testing, and connects results to clinical data. It licenses its de-identified multimodal database and AI models to pharma and biotech companies.
What is Tempus AI's revenue?
FY2025 revenue was $1,271.8 million, up from $693.4 million in 2024. For FY2026 the company guides to $1.60-$1.605 billion, about 25% growth.
How many employees does Tempus AI have?
Tempus had more than 3,800 employees at the end of 2025, including about 205 clinical sales representatives.
Who leads Tempus AI?
Eric Lefkofsky is founder, CEO and chairman, and controls the vote through dual-class stock. Jim Rogers is CFO, Tom Schoenherr is CEO of Diagnostics and Ryan Fukushima is CEO of Data and Apps.
What is Tempus AI's strategy?
It aims for about 25% long-term growth by raising diagnostics reimbursement through FDA approvals, signing multi-year pharma data and model deals, and extending its data and AI beyond oncology into areas such as cardiology and Alzheimer's.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)